Hepatitis B

Coverage of the 2017 EASL International Liver Congress

HIVandHepatitis.com coverage of the 2017 International Liver Congress, annual meeting of the European Society for the Study of the Liver, April 19-23, 2017, in Amsterdam.

Hepatitis  C

• AbbVie Combination Cures Most People with Genotype 3 Hepatitis C
• New AbbVie Hepatitis C Combination Cures 99% of People with Cirrhosis
• Triple Combination Cures Most Hepatitis C Patients with Prior DAA Failure
• Children with Hepatitis C Respond Well to Sofosbuvir/Ledipasvir
• Generic Hepatitis C Drugs Continue to Produce High Cure Rates
• Albumin Reduces Complications of Decompensated Cirrhosis and Improves Survival

Hepatitis B and D

• Besifovir and Tenofovir Exalidex Look Promising for Hepatitis B
• EASL Releases Updated Hepatitis B Guidelines at International Liver Congress
• Switching to TAF for Hepatitis B Improves Kidney Function and Bone Loss

Complications and Comorbidities

• Hepatitis C Treatment Allows 1 in 4 to Come Off Liver Transplant Waiting List
• Direct-Acting Antivirals for Hepatitis C Not Linked to Higher Liver Cancer Risk
• Curing Hepatitis C Reduces Cardiovascular Risk
• Nivolumab Increases Survival for People with Advanced Liver Cancer
• Norfloxacin Reduces Risk of Death for People with Decompensated Cirrhosis

Epidemiology and Public Health

• WHO Releases Global Hepatitis Report
• European HCV Treatment Access Survey Shows Big Variations in Eligibility